KRAS and non-small cell lung carcinoma: Established examples include KRAS mutations in non-small cell lung cancer (23%) and colorectal cancer (38%) that confer resistance to erlotinib, gefitinib (lung) or cetuximab (colorectal)[4], [10], [11].